MA23746A1 - Benzoxazepinones et benzodiazepinones inhibitrices de la synthese du cholesterol et compositions les contenant - Google Patents

Benzoxazepinones et benzodiazepinones inhibitrices de la synthese du cholesterol et compositions les contenant

Info

Publication number
MA23746A1
MA23746A1 MA24097A MA24097A MA23746A1 MA 23746 A1 MA23746 A1 MA 23746A1 MA 24097 A MA24097 A MA 24097A MA 24097 A MA24097 A MA 24097A MA 23746 A1 MA23746 A1 MA 23746A1
Authority
MA
Morocco
Prior art keywords
benzoxazepinones
benzodiazepinones
inhibitors
compositions containing
cholesterol synthesis
Prior art date
Application number
MA24097A
Other languages
English (en)
Inventor
Joel M Hawkins
Ernest S Hamanaka
Cheryl M Hayward
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA23746A1 publication Critical patent/MA23746A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MA24097A 1994-12-23 1995-12-18 Benzoxazepinones et benzodiazepinones inhibitrices de la synthese du cholesterol et compositions les contenant MA23746A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36271394A 1994-12-23 1994-12-23
PCT/IB1995/000424 WO1996020184A1 (fr) 1994-12-23 1995-06-02 Naphtyl-benzoxazepines ou benzothiazepines inhibitant la squalene synthetase

Publications (1)

Publication Number Publication Date
MA23746A1 true MA23746A1 (fr) 1996-07-01

Family

ID=23427229

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24097A MA23746A1 (fr) 1994-12-23 1995-12-18 Benzoxazepinones et benzodiazepinones inhibitrices de la synthese du cholesterol et compositions les contenant

Country Status (26)

Country Link
US (1) US5770594A (fr)
JP (1) JPH10500702A (fr)
KR (1) KR960022510A (fr)
CN (1) CN1133287A (fr)
AU (1) AU4067795A (fr)
BG (1) BG100248A (fr)
BR (1) BR9505995A (fr)
CA (1) CA2207772A1 (fr)
CZ (1) CZ344795A3 (fr)
FI (1) FI972696L (fr)
GT (1) GT199500058A (fr)
HU (1) HUT74672A (fr)
IL (1) IL116399A0 (fr)
IS (1) IS4312A (fr)
LV (1) LV11325B (fr)
MA (1) MA23746A1 (fr)
MX (1) MX9704683A (fr)
NO (1) NO955288L (fr)
OA (1) OA10204A (fr)
PE (1) PE60096A1 (fr)
PL (1) PL311997A1 (fr)
SI (1) SI9500393A (fr)
SK (1) SK158795A3 (fr)
TN (1) TNSN95133A1 (fr)
TR (1) TR199501644A2 (fr)
WO (1) WO1996020184A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048701A1 (fr) * 1996-06-20 1997-12-24 Pfizer Inc. 4,1-benzoxazepines ou 4,1-benzothiazepines et leur utilisation comme inhibiteurs de squalene synthetase
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US6403576B1 (en) * 1998-08-24 2002-06-11 The United States Of America As Represented By The Secretary Of The Navy Antifungal and antiparasitic compounds
US20020054871A1 (en) * 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
CA2389973A1 (fr) * 1999-11-04 2001-05-10 Andrx Corporation Methode de traitement de troubles lies au precurseur beta-amyloide
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
ES2328225T3 (es) * 2000-11-21 2009-11-11 Janssen Pharmaceutica Nv Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
WO2008121602A1 (fr) * 2007-03-29 2008-10-09 Smithkline Beecham Corporation Composés chimiques
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG82630A1 (en) * 1992-04-20 2001-08-21 Takeda Chemical Industries Ltd 4,1-benzoxazepin derivatives and their use
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5807834A (en) * 1994-09-20 1998-09-15 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor

Also Published As

Publication number Publication date
HUT74672A (en) 1997-01-28
WO1996020184A1 (fr) 1996-07-04
KR960022510A (ko) 1996-07-18
US5770594A (en) 1998-06-23
IS4312A (is) 1996-06-24
AU4067795A (en) 1996-07-04
CN1133287A (zh) 1996-10-16
TNSN95133A1 (fr) 1996-02-06
IL116399A0 (en) 1996-03-31
MX9704683A (es) 1997-09-30
CA2207772A1 (fr) 1996-07-04
JPH10500702A (ja) 1998-01-20
LV11325A (lv) 1996-06-20
NO955288L (no) 1996-06-24
CZ344795A3 (en) 1996-09-11
HU9503783D0 (en) 1996-04-29
LV11325B (en) 1997-02-20
FI972696A0 (fi) 1997-06-23
GT199500058A (es) 1997-06-05
SK158795A3 (en) 1997-01-08
FI972696A7 (fi) 1997-06-23
NO955288D0 (no) 1995-12-22
TR199501644A2 (tr) 1996-11-21
OA10204A (en) 1996-12-18
SI9500393A (en) 1997-04-30
FI972696L (fi) 1997-06-23
PL311997A1 (en) 1996-06-24
PE60096A1 (es) 1996-12-28
BG100248A (bg) 1996-07-31
BR9505995A (pt) 1997-12-23

Similar Documents

Publication Publication Date Title
MA23895A1 (fr) Amides therapeutiques et compositions les contenant
MA23961A1 (fr) Benzylaminopiperidines substituees et compositions les contenant
EP0868403A4 (fr) Synthese de phases "312" et leurs composites
DZ2361A1 (fr) Dérivés de 6-phénylpyridyl-2-amine et compositionspharmaceutiques les contenant
MA26426A1 (fr) Procedes et intermediaires pour la preparation de b-lactames monocycliques nouveaux et pour compositions pharmaceutiques les contenant
AP2001002270A0 (en) Metalloproteinaise inhibitors pharmaceutical compositions containing them and their pharmaceeutical uses and methods and intermediates useful for their preparation
DE69617661D1 (de) Parfümierte chemischreinigungs- und fleckenentfernungszusammensetzung
HUP9702036A3 (en) Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
HUP9702035A3 (en) Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them
HUP9702034A3 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
MA26568A1 (fr) Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase et composition pharmaceutique la contenant
MA23834A1 (fr) Procede de preparation de composes inhibiteurs de l'enzyme lp-pla2 et de compositions pharmaceutiques les contenant
DE69508859D1 (de) Verfahren zur Reinigung von (-)-n-Isopulegol sowie gereinigtes (-)-n-Isopulegol enthaltende Zitrusparfümzusammensetzungen
FR04C0032I2 (fr) Nouveaux derives de quinuclidine et composition pharmaceutique les contenant
HUP0400694A3 (en) Small molecule inhibitors of rotamase enzyme activity and pharmaceutical compositions containing the compounds
BR9610626A (pt) Métodos e composições depolicloretos de alumínio e policlorossulfatos de alumínio
AU7053496A (en) Blends of absorbable polyoxaesters containing amines and/or amido groups
MA23768A1 (fr) Composes agonistes et antagonistes des oestrogenes et compositions les contenant
PL317022A1 (en) Method of developing tolerance of t lymphocytes to tissue or organ transplants
IL115771A (en) Apolipoprotein-B synthesis inhibitors their preparation and pharmaceutical compositions containing them
EG21286A (en) Blends of organosillane compounds and their use
DE69627349D1 (de) Einrichtung zur synthese von oligonukleotiden
EP0750620A4 (fr) Composes de carbapeneme, compositions les contenant, et methodes de traitement associees
PT745605E (pt) Composicoes liquidas de halogenetos de metil-estanho
EP0737232A4 (fr) Structure et synthese modulaire de molecules contenant l'aminimide